TScan Therapeutics (TCRX): Two 2024 TCR-T Data Readouts Could Bring Significant Value

9 min read

3D virus cells attacking a DNA strand

fatido/iStock via Getty Images

TScan Therapeutics (NASDAQ:TCRX) has been able to report positive results from its phase 1 multi-arm study for the treatment of patients with several types of hematological malignancies such as acute myeloid leukemia [AML], myelodysplastic syndrome [MDS] and Acute Lymphocytic Leukemia [ALL]. It did so

Source link

You May Also Like

More From Author